Last reviewed · How we verify
Migranal nasal spray at 1 hour
Migranal nasal spray at 1 hour is a Ergot alkaloid; serotonin receptor agonist Small molecule drug developed by Thomas Jefferson University. It is currently FDA-approved for Acute migraine headache with or without aura, Cluster headache. Also known as: Dihydroergotamine (DHE).
Migranal (dihydroergotamine) is a vasoconstrictor that binds to serotonin receptors to relieve migraine headaches by narrowing blood vessels around the brain.
Migranal (dihydroergotamine) is a vasoconstrictor that binds to serotonin receptors to relieve migraine headaches by narrowing blood vessels around the brain. Used for Acute migraine headache with or without aura, Cluster headache.
At a glance
| Generic name | Migranal nasal spray at 1 hour |
|---|---|
| Also known as | Dihydroergotamine (DHE) |
| Sponsor | Thomas Jefferson University |
| Drug class | Ergot alkaloid; serotonin receptor agonist |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Dihydroergotamine is an ergot alkaloid derivative that acts as a non-selective serotonin receptor agonist, particularly at 5-HT1B and 5-HT1D receptors on cranial blood vessels and nerve terminals. This causes vasoconstriction of dilated cerebral blood vessels and inhibits the release of vasoactive neuropeptides involved in migraine pathophysiology. The nasal spray formulation provides rapid systemic absorption for acute migraine relief.
Approved indications
- Acute migraine headache with or without aura
- Cluster headache
Common side effects
- Nasal congestion or irritation
- Dizziness
- Nausea
- Vasoconstriction-related symptoms
- Taste disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Migranal nasal spray at 1 hour CI brief — competitive landscape report
- Migranal nasal spray at 1 hour updates RSS · CI watch RSS
- Thomas Jefferson University portfolio CI
Frequently asked questions about Migranal nasal spray at 1 hour
What is Migranal nasal spray at 1 hour?
How does Migranal nasal spray at 1 hour work?
What is Migranal nasal spray at 1 hour used for?
Who makes Migranal nasal spray at 1 hour?
Is Migranal nasal spray at 1 hour also known as anything else?
What drug class is Migranal nasal spray at 1 hour in?
What development phase is Migranal nasal spray at 1 hour in?
What are the side effects of Migranal nasal spray at 1 hour?
What does Migranal nasal spray at 1 hour target?
Related
- Drug class: All Ergot alkaloid; serotonin receptor agonist drugs
- Target: All drugs targeting 5-HT1B receptor, 5-HT1D receptor
- Manufacturer: Thomas Jefferson University — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Acute migraine headache with or without aura
- Indication: Drugs for Cluster headache
- Also known as: Dihydroergotamine (DHE)
- Compare: Migranal nasal spray at 1 hour vs similar drugs
- Pricing: Migranal nasal spray at 1 hour cost, discount & access